Abstract:Abstract [Background] Sorafenib, a multikinase inhibitor targeting Raf kinase and vascular endothelial growth factor receptor, is currently the only indicated therapy for patients with advanced hepatocellular carcinoma (HCC). The aberrant activation of WNT/β-catenin signaling pathway, which is associated with the carcinogenetic process of HCC, has been shown to mediate the resistance to various types of anti-cancer therapy. We hypothesized that inhibition of WNT/β-catenin signaling pathway might improve the anti-tumor effect of sorafenib in HCC. [Materials and Methods] Huh7, HepG2, PLC5, and Hep3B HCC cells were treated with sorafenib with or without inhibitors of WNT/β-catenin pathway, and evaluated for viability in vitro. WNT/β-catenin signaling inhibitors included ICG-001 which down-regulates β-catenin/TCF signaling by specifically binding to cyclic AMP response element-binding protein, and XAV939 which targets tankyrases and facilitates degradation of β-catenin. [Results] Sorafenib induced an anti-proliferative effect in HCC cells, with IC50s of 3.5±0.3 μM, 3.7±0.4 μM, 7.7±0.8 μM and 14±0.3 μM for HepG2, Huh7, PLC5, and Hep3B cells, respectively. Upon treated with 10 μM sorafenib for 24 hours, the total cellular amounts of β-catenin were significantly decreased in HepG2 and Huh7 cells, moderately decreased in PLC5 cells, and unchanged in Hep3B cells. In all HCC cells, XAV939 or ICG-001 enhanced the anti-proliferative effect of sorafenib dose-dependently. The median effect analysis showed a synergistic anti-proliferative effect for the combination of ICG-001 plus sorafenib in all HCC cells. [Conclusion] Inhibitors of WNT/β- catenin signaling pathway in combination with sorafenib resulted in an improved anti-tumor effect against HCC in vitro. (The study was supported by the grant NSC 100-2325-B-002-043 from National Science Council of Taiwan) Citation Format: Hsiao-Hui Lin, Wen-Chi Feng, Li-Chun Lu, Yu-Yun Shao, Ann-Lii Cheng, Chih-Hung Hsu. WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2052. doi:10.1158/1538-7445.AM2013-2052

[Mechanisms of sorafenib induced NB4 cell apoptosis]

Effects of Berbamine on Growth of Leukemia Cell Line NB4 and Its Mechanism

Study on the molecular mechanisms of sorafenib inhibiting human peripheral blood T cells

Sorafenib, a multi-target inhibitor, and OSU-03012, a phosphoinositide- dependent kinase-1 inhibitor, are synergistic in cytotoxicity against nasopharyngeal carcinoma cells

Studies on the Effects of Berbamine on the Human Leukemia Cell Line Nb4.

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Sorafenib May Enhance Antitumour Efficacy in Hepatocellular Carcinoma Patients by Modulating the Proportions and Functions of Natural Killer Cells.

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.

Berbamine Selectively Induces Apoptosis of Human Acute Promyelocytic Leukemia Cells Via Survivin-Mediated Pathway

Sorafenib Inhibits Activation of Human Peripheral Blood T Cells by Targeting LCK Phosphorylation

Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism

Effects of lapatinib on cell proliferation and apoptosis in NB4 cells

Abstract 2052: WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells.

Terbium(III)-cholate functionalized vesicles as luminescent indicators for the enzymatic conversion of dihydroxynaphthalene diesters.

Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non‐small cell lung cancer cells

Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity

Sorafenib induces apoptosis through reactive oxygen species production, JNK/p38 MAPK activation, and suppression of Akt/NF-kB signaling in EBV-transformed B cells (P2088)

LB-100 Sensitizes Hepatocellular Carcinoma Cells to the Effects of Sorafenib During Hypoxia by Activation of Smad3 Phosphorylation

Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.